EPA:ALCOX - Euronext Paris - Matif - FR0013018124 - Common Stock - Currency: EUR
EPA:ALCOX (6/17/2025, 7:00:00 PM)
0.2255
+0.01 (+2.5%)
The current stock price of ALCOX.PA is 0.2255 EUR. In the past month the price decreased by -0.22%. In the past year, price increased by 9.73%.
Symbol | Company Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
1ABBV.MI | ABBVIE INC | 18.69 | 293.65B | ||
4AB.DE | ABBVIE INC | 18.09 | 283.68B | ||
AMG.DE | AMGEN INC | 14.23 | 137.38B | ||
GIS.DE | GILEAD SCIENCES INC | 14.11 | 117.44B | ||
VX1.DE | VERTEX PHARMACEUTICALS INC | N/A | 99.51B | ||
1REGN.MI | REGENERON PHARMACEUTICALS | 11.98 | 49.56B | ||
ARGX.BR | ARGENX SE | 102.34 | 28.87B | ||
22UA.DE | BIONTECH SE-ADR | N/A | 21.80B | ||
IDP.DE | BIOGEN INC | 8.15 | 16.35B | ||
1EXEL.MI | EXELIXIS INC | 18.93 | 9.81B | ||
1MRNA.MI | MODERNA INC | N/A | 8.71B | ||
0QF.DE | MODERNA INC | N/A | 8.67B |
Nicox SA is an ophthalmology company. The company is headquartered in Biot, Paca and currently employs 5 full-time employees. The company is engaged in the field of the research, development and future commercialization of investigational drugs for ophthalmological diseases. The Company’s aim is to build a portfolio of therapeutic products addressing the needs of eye care practitioners and patients. Nicox SA offers its customers the Xailin range of ocular lubricants and AdenoPlus, a diagnostic test that aids in the differential diagnosis of acute conjunctivitis. The firm has also products in the pipeline, such as VESNEO (a drug-candidate for treating glaucoma) and AC-170 (for allergic conjunctivis). The company has a direct commercial presence in Germany, France, the United Kingdom, Italy and Spain, as well as partnerships with local distributors in a number of key international markets.
NICOX SA
Sundesk Sophia Antipolis, Batiment C, Emerald Square, rue Evariste Galois
BIOT PACA FR
Employees: 5
Phone: 33497245300
The current stock price of ALCOX.PA is 0.2255 EUR. The price increased by 2.5% in the last trading session.
The exchange symbol of NICOX SA is ALCOX and it is listed on the Euronext Paris - Matif exchange.
ALCOX.PA stock is listed on the Euronext Paris - Matif exchange.
9 analysts have analysed ALCOX.PA and the average price target is 1.02 EUR. This implies a price increase of 352.33% is expected in the next year compared to the current price of 0.2255. Check the NICOX SA stock analysts ratings, price target forecast and up-and down grades for more detailed information.
NICOX SA (ALCOX.PA) has a market capitalization of 15.65M EUR. This makes ALCOX.PA a Nano Cap stock.
NICOX SA (ALCOX.PA) currently has 5 employees.
NICOX SA (ALCOX.PA) has a support level at 0.22 and a resistance level at 0.23. Check the full technical report for a detailed analysis of ALCOX.PA support and resistance levels.
The Revenue of NICOX SA (ALCOX.PA) is expected to decline by -100% in the next year. Check the estimates tab for more information on the ALCOX.PA EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ALCOX.PA does not pay a dividend.
NICOX SA (ALCOX.PA) will report earnings on 2025-07-16.
NICOX SA (ALCOX.PA) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.31).
ChartMill assigns a fundamental rating of 1 / 10 to ALCOX.PA. ALCOX.PA has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months ALCOX.PA reported a non-GAAP Earnings per Share(EPS) of -0.31. The EPS increased by 23.81% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -92.83% | ||
ROE | -653.37% | ||
Debt/Equity | 4.4 |
ChartMill assigns a Buy % Consensus number of 84% to ALCOX.PA. The Buy consensus is the average rating of analysts ratings from 9 analysts.
For the next year, analysts expect an EPS growth of 16% and a revenue growth -100% for ALCOX.PA